Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


01.04.2019

1 Am J Clin Oncol
1 Am J Respir Cell Mol Biol
1 Ann Oncol
1 Ann Thorac Surg
6 BMC Cancer
1 BMJ
2 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
3 Clin Lung Cancer
1 Clin Nucl Med
1 Eur Respir J
2 J Cancer Res Clin Oncol
3 J Surg Oncol
1 J Thorac Cardiovasc Surg
6 J Thorac Oncol
1 JAMA Oncol
3 Lancet Respir Med
1 Oncogene
2 Oncologist
1 PLoS Comput Biol
1 PLoS One
1 Semin Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. RAPHAEL J, Vincent M, Boldt G, Shah PS, et al
    Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2019 Mar 25. doi: 10.1097/COC.0000000000000533.
    PubMed     Text format     Abstract available


    Am J Respir Cell Mol Biol

  2. LEACH SM, Finigan J, Vasu VT, Mishra R, et al
    The Kinome of Human Alveolar Type II and Basal Cells, and its Reprogramming in Lung Cancer.
    Am J Respir Cell Mol Biol. 2019 Mar 27. doi: 10.1165/rcmb.2018-0283.
    PubMed     Text format     Abstract available


    Ann Oncol

  3. PETERS S, Reck M, Smit EF, Mok T, et al
    How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
    Ann Oncol. 2019 Mar 26. pii: 5420157. doi: 10.1093.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  4. CHEN D, Mao Y, Wen J, She Y, et al
    Tumor Spread Through Air Spaces in Non-Small Cell Lung Cancer: a systematic review and meta-analysis.
    Ann Thorac Surg. 2019 Mar 23. pii: S0003-4975(19)30400.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. KIM EY, Kim A, Lee G, Lee H, et al
    Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
    BMC Cancer. 2018;18:1221.
    PubMed     Text format     Abstract available

  6. SUN H, Gao D
    Propofol suppresses growth, migration and invasion of A549 cells by down-regulation of miR-372.
    BMC Cancer. 2018;18:1252.
    PubMed     Text format     Abstract available

  7. ZHAO P, Wu J, Lu F, Peng X, et al
    Correction to: The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
    BMC Cancer. 2019;19:269.
    PubMed     Text format     Abstract available

  8. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Text format     Abstract available

  9. YANG LH, Han Y, Li G, Xu HT, et al
    Correction to: Axin gene methylation status correlates with radiosensitivity of lung cancer cells.
    BMC Cancer. 2019;19:268.
    PubMed     Text format     Abstract available

  10. CHEN Y, Tsang YS, Chou X, Hu J, et al
    A lung cancer patient with deep vein thrombosis:a case report and literature review.
    BMC Cancer. 2019;19:285.
    PubMed     Text format     Abstract available


    BMJ

  11. MACONACHIE R, Mercer T, Navani N, McVeigh G, et al
    Lung cancer: diagnosis and management: summary of updated NICE guidance.
    BMJ. 2019;364:l1049.
    PubMed     Text format    


    Cancer Lett

  12. EXPOSITO F, Villalba M, Redrado M, de Aberasturi AL, et al
    Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery.
    Cancer Lett. 2019 Mar 21. pii: S0304-3835(19)30169.
    PubMed     Text format     Abstract available

  13. LI L, Wang Y, Jiao L, Lin C, et al
    Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer.
    Cancer Lett. 2019 Mar 22. pii: S0304-3835(19)30183.
    PubMed     Text format     Abstract available


    Cancer Res

  14. SOHONI S, Ghosh P, Wang T, Kalainayakan SP, et al
    Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells.
    Cancer Res. 2019 Mar 22. pii: 0008-5472.CAN-18-2156.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  15. HEIGENER DF, Kerr KM, Laing GM, Mok TSK, et al
    Redefining treatment paradigms in first-line advanced non-small cell lung cancer.
    Clin Cancer Res. 2019 Mar 25. pii: 1078-0432.CCR-18-1894.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  16. RICCIUTI B, Genova C, Bassanelli M, De Giglio A, et al
    Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
    Clin Lung Cancer. 2019 Feb 27. pii: S1525-7304(19)30020.
    PubMed     Text format     Abstract available

  17. HIRANUMA O, Uchino J, Yamada T, Chihara Y, et al
    Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
    Clin Lung Cancer. 2019 Feb 27. pii: S1525-7304(19)30066.
    PubMed     Text format     Abstract available

  18. BUDNIK J, DeNunzio NJ, Singh DP, Milano MT, et al
    Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.
    Clin Lung Cancer. 2019 Mar 4. pii: S1525-7304(19)30067.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  19. WANG LJ, Wu HB, Zhang Y, Zhou WL, et al
    A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT.
    Clin Nucl Med. 2018 Dec 17. doi: 10.1097/RLU.0000000000002419.
    PubMed     Text format     Abstract available


    Eur Respir J

  20. DETILLON DEMA, Aarts MJ, De Jaeger K, Van Eijck CHJ, et al
    Video-assisted thoracic lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer in elderly patients: a propensity matched comparative analysis.
    Eur Respir J. 2019 Mar 28. pii: 13993003.01561-2018.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  21. HAWKINS PG, Sun Y, Dess RT, Jackson WC, et al
    Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2019 Mar 28. pii: 10.1007/s00432-019-02903.
    PubMed     Text format     Abstract available

  22. AHN BC, Pyo KH, Xin CF, Jung D, et al
    Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
    J Cancer Res Clin Oncol. 2019 Mar 25. pii: 10.1007/s00432-019-02899.
    PubMed     Text format     Abstract available


    J Surg Oncol

  23. BLISS LA, Strong EA, Gamblin TC
    Surgical resectability of multisite metastatic colorectal cancer: Pushing the limits while appropriately selecting patients.
    J Surg Oncol. 2019 Feb 25. doi: 10.1002/jso.25419.
    PubMed     Text format     Abstract available

  24. LEE RM, Cardona K, Russell MC
    Historical perspective: Two decades of progress in treating metastatic colorectal cancer.
    J Surg Oncol. 2019 Feb 26. doi: 10.1002/jso.25431.
    PubMed     Text format     Abstract available

  25. PHILLIPS JD, Hasson RM
    Surgical management of colorectal lung metastases.
    J Surg Oncol. 2019;119:629-635.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  26. LATIF MJ, Tan KS, Molena D, Huang J, et al
    Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2019 Feb 12. pii: S0022-5223(19)30351.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  27. BOUSEMA JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, et al
    Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis.
    J Thorac Oncol. 2019 Mar 21. pii: S1556-0864(19)30211.
    PubMed     Text format    

  28. LI C, Liang H, Zhong N, He J, et al
    Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography: A Population Level Analysis.
    J Thorac Oncol. 2019;14:e82-e84.
    PubMed     Text format    

  29. QIN J, Wang J, Lin X, Wang J, et al
    Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e65-e68.
    PubMed     Text format    

  30. ARJYAL L
    Concurrent Chemoradiation in Elderly Patients with Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e63.
    PubMed     Text format    

  31. LU S, Li Z
    Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:580-582.
    PubMed     Text format    

  32. CAMIDGE DR, Dziadziuszko R, Peters S, Mok T, et al
    Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.
    J Thorac Oncol. 2019 Mar 19. pii: S1556-0864(19)30210.
    PubMed     Text format     Abstract available


    JAMA Oncol

  33. MOR V, Wagner TH, Levy C, Ersek M, et al
    Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.
    JAMA Oncol. 2019 Mar 28. pii: 2729064. doi: 10.1001/jamaoncol.2019.0081.
    PubMed     Text format     Abstract available


    Lancet Respir Med

  34. RECK M, Mok TSK, Nishio M, Jotte RM, et al
    Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Lancet Respir Med. 2019 Mar 25. pii: S2213-2600(19)30084.
    PubMed     Text format     Abstract available

  35. BOFFA D
    A new low represents a new high in surgical safety.
    Lancet Respir Med. 2018;6:888-889.
    PubMed     Text format    

  36. PACHECO JM, Camidge DR
    Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations.
    Lancet Respir Med. 2019 Mar 25. pii: S2213-2600(19)30112.
    PubMed     Text format    


    Oncogene

  37. CASADO-MEDRANO V, Barrio-Real L, Wang A, Cooke M, et al
    Distinctive requirement of PKCepsilon in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells.
    Oncogene. 2019 Mar 28. pii: 10.1038/s41388-019-0796.
    PubMed     Text format     Abstract available


    Oncologist

  38. WEN S, Dai L, Wang L, Wang W, et al
    Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Oncologist. 2019 Mar 22. pii: theoncologist.2018-0572.
    PubMed     Text format     Abstract available

  39. ABDEL KARIM N, Kelly K
    Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
    Oncologist. 2019 Mar 26. pii: theoncologist.2018-0112.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  40. DAMIANI C, Maspero D, Di Filippo M, Colombo R, et al
    Integration of single-cell RNA-seq data into population models to characterize cancer metabolism.
    PLoS Comput Biol. 2019;15:e1006733.
    PubMed     Text format     Abstract available


    PLoS One

  41. LEE JH, Kim TH, Lee S, Han K, et al
    High versus low attenuation thresholds to determine the solid component of ground-glass opacity nodules.
    PLoS One. 2018;13:e0205490.
    PubMed     Text format     Abstract available


    Semin Oncol

  42. CAMERON L, Sullivan R, Luey B, Solomon B, et al
    Mind the Graph: Foregone Health Gains in Lung Cancer.
    Semin Oncol. 2018;45.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: